- Home
- NTRB vs IMRX Comparison
NTRB vs IMRX Comparison
Compare NTRB & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- IMRX
- Stock Information
- Founded
- NTRB 2016
- IMRX 2008
- Country
- NTRB United States
- IMRX United States
- Employees
- NTRB N/A
- IMRX N/A
- Industry
- NTRB Industrial Specialties
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- IMRX Health Care
- Exchange
- NTRB Nasdaq
- IMRX Nasdaq
- Market Cap
- NTRB 77.9M
- IMRX 73.2M
- IPO Year
- NTRB N/A
- IMRX 2021
- Fundamental
- Price
- NTRB $7.10
- IMRX $2.09
- Analyst Decision
- NTRB
- IMRX Buy
- Analyst Count
- NTRB 0
- IMRX 7
- Target Price
- NTRB N/A
- IMRX $12.60
- AVG Volume (30 Days)
- NTRB 42.2K
- IMRX 3.9M
- Earning Date
- NTRB 12-11-2024
- IMRX 11-07-2024
- Dividend Yield
- NTRB N/A
- IMRX N/A
- EPS Growth
- NTRB N/A
- IMRX N/A
- EPS
- NTRB N/A
- IMRX N/A
- Revenue
- NTRB $1,803,816.00
- IMRX N/A
- Revenue This Year
- NTRB N/A
- IMRX N/A
- Revenue Next Year
- NTRB N/A
- IMRX N/A
- P/E Ratio
- NTRB N/A
- IMRX N/A
- Revenue Growth
- NTRB N/A
- IMRX N/A
- 52 Week Low
- NTRB $1.53
- IMRX $1.00
- 52 Week High
- NTRB $9.60
- IMRX $8.89
- Technical
- Relative Strength Index (RSI)
- NTRB 58.43
- IMRX 47.54
- Support Level
- NTRB $7.05
- IMRX $1.90
- Resistance Level
- NTRB $8.49
- IMRX $2.51
- Average True Range (ATR)
- NTRB 0.62
- IMRX 0.24
- MACD
- NTRB 0.09
- IMRX -0.08
- Stochastic Oscillator
- NTRB 50.18
- IMRX 23.75
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.